

KESSLER, TOBIAS, PD DR. MED.

GENERAL INFORMATION



Post Doc / Consultant in Neurology

University Hospital Heidelberg, Department of Neurology
Im Neuenheimer Feld 400
69120 Heidelberg, Germany

A03

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
04/2021	Neurology Board certification
2007-2014	Medical training at the Heidelberg University Medical School, visits abroad in London, Singapore and Incheon
06/2006	Higher education entrance qualification at the Albert-Einstein-Schule in Groß-Bieberau, Germany.

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
01/2023	Habilitation in Neurology at the Medical Faculty of the Heidelberg University
05/2016	MD thesis in oncology at the University of Heidelberg. Experimental research was done at the German Cancer Research Center (DKFZ) in Heidelberg, Clinical Cooperation Unit Neurooncology (head and supervisor: Prof. Dr. W. Wick) about antiangiogenic strategies in PTEN deficient glioblastoma. Summa cum laude

PROFESSIONAL EXPERIENCE

Year(s)	Experience
Since 04/2023	Attending in Neurology, Heidelberg University Hospital
Since 2021	Resident, since 04/2021 consultant in Neurology, Heidelberg University Hospital
2020	Resident in Psychiatry, Vitos Klinik in Heppenheim, Germany
Since 2016	Postdoctoral researcher at the German Cancer Research Center in Heidelberg, Clinical Cooperation Unit Neurooncology (head: Prof. Dr. W. Wick)
2014-2019	Resident in neurology, Neurology Clinic, University Hospital Heidelberg (chairman: Prof. Dr. W. Hacke - since 10/2014 Prof. Dr. W. Wick). Clinical focus on brain tumors and emergency medicine in neurology

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	Qualifications/Roles/Responsibilities
Since 01/2023	Deputy Director of ASD Concepts - Institute for patient oriented care programs
Since 05/2019	Project leader (A03) in the SFB UNITE Glioblastoma (SFB1389)
2019-2020	Spokesperson of the young NOA (Neuroonkologische Arbeitsgemeinschaft)
2017	WMA award of the World Federation of Neuro-Oncology Societies (WFNOS) for the best oral presentation at the 2017 WFNOS congress in Zürich
Since 2008	Co-founder, shareholder and medical consultant of ASD Concepts

SELECTED PUBLICATIONS

1. [Kessler T](#), Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. **Neuro Oncol**. 2018 Feb 19;20(3):367-379. doi: 10.1093/neuonc/nox160. PMID: 29016808; PMCID: PMC5817966.
2. Pfaff E*, [Kessler T*](#), Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW#, Wick W#, Sahm F#. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. **Neuro Oncol**. 2018 May 18;20(6):826-837. doi: 10.1093/neuonc/nox216. PMID: 29165638; PMCID: PMC5961072.
3. Wick W, [Kessler T](#). Heterogeneity glioblastoma atlas: a shared resource. **Nat Rev Neurol**. 2018 Aug;14(8):453-454. doi: 10.1038/s41582-018-0038-3.
4. Wick A*, [Kessler T*](#), Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bölting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, Weller M, Wick W. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. **Neuro Oncol**. 2020 Aug 17;22(8):1162-1172. doi: 10.1093/neuonc/noaa033. PMID: 32064499; PMCID: PMC7594575.
5. [Kessler T](#), Berberich A, Sadik A, Sahm F, Gorlia T, Meisner C, Hoffmann DC, Wick A, Kickingereeder P, Rübmann P, Bendszus M, Opitz C, Weller M, van den Bent M, Stupp R, Winkler F, Brandes A, von Deimling A, Platten M, Wick W. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. **Cancer Med**. 2020 Nov;9(22):8373-8385. doi: 10.1002/cam4.3447. Epub 2020 Sep 29. PMID: 32991787; PMCID: PMC7666733.
6. [Kessler T](#), Wick W. Oncolytic virotherapy: Potentially a game-changing tumor treatment. **Cancer Cell**. 2021 Jun 14;39(6):753-755. doi: 10.1016/j.ccell.2021.05.014. PMID: 34129821.
7. Schmid D, Warnken U, Latzer P, Hoffmann DC, Roth J, Kutschmann S, Jaschonek H, Rübmann P, Foltyn M, Vollmuth P, Winkler F, Seliger C, Felix M, Sahm F, Haas J, Reuss D, Bendszus M, Wildemann B, von Deimling A, Wick W, [Kessler T](#). Diagnostic Biomarkers from Proteomic Characterization of Cerebrospinal Fluid in Patients with Brain Malignancies. **J Neurochem**. 2021 Jul;158(2):522-538. doi: 10.1111/jnc.15350. Epub 2021 Apr 9. PMID: 33735443.
8. Wick A, Sander A, Koch M, Bendszus M, Combs S, Haut T, Dormann A, Walter S, Pertz M, Merkle-Lock J, Selkrig N, Limprecht R, Baumann L, Kieser M, Sahm F, Schlegel U, Winkler F, Platten M, Wick W, [Kessler T](#). Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. **BMC Cancer**. 2022 Jun 13;22(1):645. doi: 10.1186/s12885-022-09720-z. PMID: 35692047; PMCID: PMC9190129
9. Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, Jabali A, Hai L, [Kessler T](#), Azofin DD, Weil S, Kourtesakis A, Sievers P, Habel A, Breckwoldt MO, Karreman MA, Ratliff M, Messmer JM, Yang Y, Reyhan E, Wendler S, Löb C, Mayer C, Figarella K, Osswald M, Solecki G, Sahm F, Garaschuk O, Kuner T, Koch P, Schlesner M, Wick W, Winkler F. Autonomous rhythmic activity in glioma networks drives brain tumour growth. **Nature**. 2023 Jan;613(7942):179-186. doi: 10.1038/s41586-022-05520-4. Epub 2022 Dec 14. PMID: 36517594.
10. [Kessler T](#), Schrimpf D, Doerner L, Hai L, Kaulen LD, Ito J, van den Bent M, Taphoorn M, Brandes AA, Idbaih A, Dômont J, Clement PM, Campone M, Bendszus M, von Deimling A, Sahm F, Platten M, Wick W, Wick A. Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial. **Clin Cancer Res**. 2023 Jul 26:CCR-23-0926. doi: 10.1158/1078-0432.CCR-23-0926. Epub ahead of print. PMID: 37494539